In a protocol-defined sub-study Fumagalli et al. used NeoALTTO tumor samples in order to evaluate potential associations between intratumoral HER2 gene expression levels and PAM50 subtypes, and the outcome parameters pCR and EFS. This evidence concerns the gene ERBB2 and neoplasm.